Whether the timing of patient randomization interferes with the assessment of the efficacy of ruxolitinib for severe COVID-19

Detalles Bibliográficos
Autores principales: Li, Hailan, Liu, Huaping
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Academy of Allergy, Asthma & Immunology 2020
Materias:
Correspondence
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7498226/
https://www.ncbi.nlm.nih.gov/pubmed/32980157
http://dx.doi.org/10.1016/j.jaci.2020.09.002
_version_ 1783583464822407168
author Li, Hailan
Liu, Huaping
author_facet Li, Hailan
Liu, Huaping
author_sort Li, Hailan
collection PubMed
description
format Online
Article
Text
id pubmed-7498226
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher American Academy of Allergy, Asthma & Immunology
record_format MEDLINE/PubMed
spelling pubmed-74982262020-09-18 Whether the timing of patient randomization interferes with the assessment of the efficacy of ruxolitinib for severe COVID-19 Li, Hailan Liu, Huaping J Allergy Clin Immunol Correspondence American Academy of Allergy, Asthma & Immunology 2020-12 2020-09-17 /pmc/articles/PMC7498226/ /pubmed/32980157 http://dx.doi.org/10.1016/j.jaci.2020.09.002 Text en © 2020 American Academy of Allergy, Asthma & Immunology. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Correspondence
Li, Hailan
Liu, Huaping
Whether the timing of patient randomization interferes with the assessment of the efficacy of ruxolitinib for severe COVID-19
title Whether the timing of patient randomization interferes with the assessment of the efficacy of ruxolitinib for severe COVID-19
title_full Whether the timing of patient randomization interferes with the assessment of the efficacy of ruxolitinib for severe COVID-19
title_fullStr Whether the timing of patient randomization interferes with the assessment of the efficacy of ruxolitinib for severe COVID-19
title_full_unstemmed Whether the timing of patient randomization interferes with the assessment of the efficacy of ruxolitinib for severe COVID-19
title_short Whether the timing of patient randomization interferes with the assessment of the efficacy of ruxolitinib for severe COVID-19
title_sort whether the timing of patient randomization interferes with the assessment of the efficacy of ruxolitinib for severe covid-19
topic Correspondence
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7498226/
https://www.ncbi.nlm.nih.gov/pubmed/32980157
http://dx.doi.org/10.1016/j.jaci.2020.09.002
work_keys_str_mv AT lihailan whetherthetimingofpatientrandomizationinterfereswiththeassessmentoftheefficacyofruxolitinibforseverecovid19
AT liuhuaping whetherthetimingofpatientrandomizationinterfereswiththeassessmentoftheefficacyofruxolitinibforseverecovid19

Ejemplares similares